GeneDx Reaffirms 2026 Guidance After Strong Q4, Full-Year 2025 Results

Got story updates? Submit your updates here. ›

GeneDx, a Gaithersburg, Maryland-based clinical genetic testing company, has reaffirmed its full-year 2026 revenue guidance of $540 million to $555 million after delivering 27% and 41% revenue growth in Q4 and full-year 2025, respectively. The majority of the company's Q4 revenue came from its exome and genome testing business, which grew 32% year-over-year. For the full year 2025, GeneDx's revenue grew 41% to $427.5 million, surpassing analyst estimates.

Why it matters

GeneDx's strong financial performance in 2025, particularly in its core exome and genome testing business, demonstrates the company's ability to capitalize on the growing demand for advanced genetic testing services. This positions GeneDx well to continue its growth trajectory and maintain its position as a leading provider of clinical genetic testing solutions.

The details

In Q4 2025, GeneDx's exome and genome testing business generated $104.0 million in revenue, up 32% from the prior-year period. The company's full-year 2025 exome and genome testing revenue grew 54% to $360.3 million, driven by a 31% increase in test volume to 97,271 tests. Overall, GeneDx's 2025 revenue grew 41% to $427.5 million, surpassing the analyst consensus estimate of $427.0 million.

• GeneDx reported its Q4 and full-year 2025 results on February 23, 2026.
• For the full year 2025, GeneDx's revenue grew 41% compared to 2024.

What’s next

GeneDx has reaffirmed its full-year 2026 revenue guidance of $540 million to $555 million, along with expectations for 33% to 35% volume growth in its exome and genome testing business.